Phase III Trials Of Covid Drug Movfor Show Positive Results, Says Hetero

Add as a preferred source on Google

Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.

The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16, 2022, demonstrated that Molnupiravir along with the standard of care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone.

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug, the Hyderabad-based drugmaker said in a statement.

No fatalities were reported during the study, it added.

Under the Phase III trials, one of the studies included 1,218 COVID-19 patients, it said. The study enrolled eligible patients, within five days of symptom onset, were administered with Molnupiravir capsules(800 mg twice daily) for five days, it added.

Hetero entered into a non-exclusive voluntary licensing agreement with MSD in April 2021 for the manufacturing and distribution of Molnupiravir for the treatment of COVID-19.

Under this licensing deal, Hetero was allowed to expand access to Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies.

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.